Literature DB >> 12629954

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

Norman L Keltner1, Vicki Johnson.   

Abstract

Schizophrenia places an incredible burden on patients, families, communities, and governments, therefore intense efforts to find therapeutic responses to this illness continue. The traditional antipsychotics were discovered by chance, the atypical antipsychotics were configured to preserve "what worked" while adding and eliminating important effects, and the next generation continues to evolve in an attempt to improve on previous generations. Aripiprazole is extoled as a new generation of antipsychotic drugs. Information to date suggests it is an effective antipsychotic with a remarkable side effect profile. We are hopeful this drug will provide a relief for the suffering associated with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12629954     DOI: 10.1111/j.1744-6163.2002.tb01566.x

Source DB:  PubMed          Journal:  Perspect Psychiatr Care        ISSN: 0031-5990            Impact factor:   2.186


  10 in total

1.  Aripiprazole-induced seizure: a second case report.

Authors:  Che-Lin Yueh; Sung-Lin Yu; Hsiao-Min Chen; Bo-Jian Wu; Wen-Ching Chen
Journal:  BMJ Case Rep       Date:  2009-07-14

2. 

Authors:  Clare Lambert; Constadina Panagiotopoulos; Jana Davidson; Ran D Goldman
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

Review 3.  Classics in Chemical Neuroscience: Aripiprazole.

Authors:  Austen B Casey; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

4.  Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties.

Authors:  Zhangcheng Chen; Luyu Fan; Huan Wang; Jing Yu; Dengyu Lu; Jianzhong Qi; Fen Nie; Zhipu Luo; Zhen Liu; Jianjun Cheng; Sheng Wang
Journal:  Nat Neurosci       Date:  2021-12-09       Impact factor: 24.884

Review 5.  Aripiprazole: in acute mania associated with bipolar I disorder.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Second-generation antipsychotics in children: Risks and monitoring needs.

Authors:  Clare Lambert; Constadina Panagiotopoulos; Jana Davidson; Ran D Goldman
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

10.  Improvement in quality of life in depressed patients following verum acupuncture or electroacupuncture plus paroxetine: A randomized controlled study of 157 cases.

Authors:  Shenghui Ma; Shanshan Qu; Yong Huang; Junqi Chen; Renyong Lin; Chongqi Wang; Ganlong Li; Canghuan Zhao; Shenchang Guo; Zhangjin Zhang
Journal:  Neural Regen Res       Date:  2012-09-25       Impact factor: 5.135

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.